Perspective Therapeutics (CATX) Current Deferred Revenue (2024)
Perspective Therapeutics recorded quarterly Current Deferred Revenue of $1.4 million in Q4 2024, little changed quarter-over-quarter from $1.4 million in Q3 2024.
Perspective Therapeutics' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $1.4 million for Q4 2024.
- In Q4 2024, Current Deferred Revenue changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2024 stood at $1.4 million (changed N/A YoY), while the FY2024 annual figure was $1.4 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $1.4 million for Q4 2024 at Perspective Therapeutics, roughly flat from $1.4 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.4 million in Q1 2024 to a low of $1.4 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Perspective Therapeutics | 380.23 Mn | 380.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.40 Mn |